Black patients at a heightened risk for heart disease cut their CV mortality risk by 11% in a study that explored the cardiac benefits of the Transcendental Meditation technique.

The FDA has approved Novo Nordisk’s Ozempic—once-weekly semaglutide—for an expanded indication of CV risk reduction in people with type 2 diabetes and established heart disease.

Women’s blood vessels age at a faster rate than men’s, researchers from the Smidt Heart Institute at Cedars-Sinai reported this month—a finding that could explain some of the considerable sex gaps in CVD in men and women.

One Minneapolis cardiologist is concerned that people following the trendy Keto diet aren’t worrying enough about their fat intake.

Pharmaceutical company Novartis has partnered with the U.K.’s National Health Service to study inclisiran, an investigational cholesterol-lowering drug that experts project could save 30,000 lives over the next decade.

U.K.-based drug giant AstraZeneca announced Jan. 13 it would be halting its Phase III trial of Epanova, a medication comprised of omega-3 carboxylic acids, early due to disappointing data.

The future of diabetes diagnosis and management could lie in a “smart” LED contact lens, a study published in Nature Reviews Materials suggests.

A group of scientists from the University of Alabama at Birmingham have derived predictive equations to identify adults at a high risk of having nocturnal hypertension or nondipping systolic blood pressure—both hard-to-catch conditions that can raise a person’s risk for CVD.